Enantiospecific Synthesis of the C-9 to C-18 Fragment of Macbecins I and II

Raymond Baker,*† W. Jon Cummings, Jerome F. Hayes, and Anil Kumar

Department of Chemistry, The University, Southampton SO9 5NH, U.K.

The synthesis of the C-9 to C-18 fragment of macbecins I and II has been accomplished *via* a novel cyclisation and stereospecific cuprate opening of a chiral epoxide.

Macbecins I (**1**) and II (**2**) are new antibiotics isolated from the fermentation broth of Nocardia sp. (No. C-14919) exhibiting antibacterial, antifungal, antiprotozoal, and antitumour activities.[1,2] Their structure and absolute configuration have been determined by Muroi *et al.*[3] and they have been assigned to the ansamycin group of antibiotics which includes geldanamycin,[4] herbimycin,[5] and ansamitocin.[6] There has been a steadily growing interest in macbecin both clinically[7] and synthetically,[8] although to date no synthesis has been reported. We now report a synthesis of a fragment of macbecins I and II.

Retrosynthetic analysis divided the C-9—C-18 fragment of macbecin into two segments, the epoxide (**3**) and the vinyl iodide (**4**). It was anticipated that formation of the C-15–C-16 bond would be by reaction of the appropriate vinyl cuprate reagent with the chiral epoxide (**3**). The required epoxide was obtained in two steps from (*E*)-crotyl alcohol (**5**). Sharpless epoxidation[9] [(+)-di-isopropyl tartrate, $Ti(OPr^i)_4$, Bu^tOOH, CH_2Cl_2, −20 °C, 24 h] afforded the epoxy alcohol in 40% yield and in 95% enantiomeric excess (e.e.), b.p. (Kugelrohr) 78 °C at 15 mm Hg; $[\alpha]_D^{22}$ −53.1° (*c* 6.0, benzene) lit.[9] $[\alpha]_D^{22}$ −54.5° (*c* 0.24, benzene), which was subsequently protected as the t-butyldimethylsilyl ether in quantitative yield to afford the required epoxide (**3**) (Scheme 1) $[\alpha]_D^{22}$ −23.2° (*c* 0.11, CH_2Cl_2); δ_H (360 MHz; $CDCl_3$) 3.72 (1H, dd, *J* 11.6, 2.5 Hz), 3.59 (1H, dd, *J* 11.6, 2.5 Hz), 2.83 (1H, dq, *J* 5, 2.4 Hz), 2.73 (1H, m), 1.32 (3H, d, *J* 5 Hz), 0.88 (9H, s), 0.06 (3H, s), 0.05 (3H, s); 95% e.e. [determined by 360 MHz ^1H n.m.r. using $Eu(fod)_3$ shift reagent; fod = 1,1,1,2,2,3,3-heptafluoro-7,7-dimethyloctane-4,6-dionate].

† *Present address:* Merck Sharp and Dohme Research Laboratories, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR.



Scheme 1. *Reagents:* i, $Ti(OPr^i)_4$, (+)-di-isopropyl tartrate, Bu^tOOH, CH_2Cl_2, −20 °C, 24 h; ii, Bu^tMe_2SiCl, imidazole.

The synthesis of the C-9—C-15 fragment is shown in Scheme 2;‡ carboalumination[10] of propargyl alcohol [$(C_5H_5)_2ZrCl_2$, Me_3Al, $ClCH_2CH_2Cl$, room temp., 12 h, quench at −30 °C, I_2] gave the expected (*E*)-trisubstituted allylic alcohol in 43% yield. Manganese dioxide oxidation in dichloromethane yielded the extremely unstable and volatile aldehyde (**6**), which was not normally isolated but filtered in dichloromethane through Celite to remove the MnO_2. The solution was dried over freshly activated 4 Å molecular sieves and used directly in the next step. The enantioselective aldol[11] required to yield the appropriate stereochemistry at C-12 and C-13 was conducted between (**6**) and the preformed (*Z*)-9-borabicyclo[3.3.1]nonane (9-BBN) enolate of propanoyl oxazolidinone [(*Z*)-enolate formation: propanoyl oxazolidinone (**7**), 9-BBN·trifluoromethanesulphonyl (·Tf), Pr^i_2NEt, CH_2Cl_2, 0 °C, 1.5 h]. The aldol was conducted with the (*Z*)-enolate and (**6**) in CH_2Cl_2 at −78 °C for 1.5 h followed by the same time at room temperature. The reaction was quenched with NaH_2PO_4 and worked-up with excess of H_2O_2 at 0 °C. This yielded the expected *erythro* isomer (**8**) in 95% e.e. and 58% chemical yield as a white crystalline solid, m.p. 106 °C, $[\alpha]_D^{22}$ + 134° (*c* 1.3, CH_2Cl_2); δ_H (360 MHz; $CDCl_3$) 7.40 (5H, m), 6.43 (1H, s), 5.71 (1H, d, *J* 7.3 Hz), 4.78 (1H, dq, *J* 7.3, 7.0 Hz), 4.52 (1H, s), 4.02 (1H, dq, *J* 6.4, 2.3 Hz), 3.18 (1H, d, *J* 2.8 Hz; removable with D_2O), 1.79 (3H, s), 1.12 (3H, d, *J* 7.0 Hz), 0.85 (3H, d, *J* 6.4 Hz). Protection of the alcohol as its t-butyldimethylsilyl ether gave (**9**) in quantitative yield $[\alpha]_D^{22}$ −10.43° (*c* 0.94, CH_2Cl_2). Removal of the chiral

Scheme 2. *Reagents:* i, $(C_5H_5)_2ZrCl_2$, Me_3Al, $ClCH_2CH_2Cl$, room temp., 12 h; quench −30 °C, I_2; ii, MnO_2, CH_2Cl_2, room temp., 12 h; iii, (**7**), 9-BBN·Tf, Pr^i_2NEt, CH_2Cl_2, (**6**), −78 °C; iv, Bu^tMe_2Si·Tf, 2,6-lutidine, 0 °C, 2 h; v, $LiBH_4$, THF, room temp., 18 h; vi, $(COCl)_2$, dimethyl sulphoxide, Et_3N, −60 °C, 1.5 h; vii, Bu^tOAc, LDA, THF, −78 °C, 2 h; viii, TFA·H_2O, 9 : 1, CH_2Cl_2, room temp., 96 h; ix, MsCl, Et_3N, CH_2Cl_2 reflux, 12 h; x, DIBAL, toluene, −78 °C, 1 h; xi, Amberlite–H^+, MeOH, room temp., 18 h; xii, (**4**), Bu^tLi (2 equiv.), Et_2O, −80 °C, CuCN (1 equiv.), (**3**) (2 equiv.), Et_2O, −40 °C, 4 h, −20 °C, 24 h.

‡ All isolated compounds described were characterised by 360 MHz n.m.r., i.r., and mass spectrometric data which were in accord with the assigned structures.

auxiliary with $LiBH_4$, and Swern oxidation[12] of the resulting alcohol afforded the aldehyde (**10**) $[\alpha]_D^{22}$ + 33.8° (*c* 0.9, CH_2Cl_2), in 71% overall yield.

The aldehyde (**10**) was then treated with lithio-t-butyl acetate [formed from t-butyl acetate, lithium di-isopropylamide (LDA), tetrahydrofuran (THF), −78 °C, 20 min] under argon to yield the aldol product (**11**) in quantitative yield. These epimeric β-hydroxyesters were then treated with a 9 : 1 trifluoroacetic acid (TFA)–water mixture at 25 °C for 96 h to yield the hydroxylactones (**12b**,**a**) in 68% yield in a 5 : 1 axial/equatorial ratio at C-11; δ_H (360 MHz; $CDCl_3$) (equatorial isomer) 6.49 (1H, s), 4.70 (1H, s), 4.32 (1H, ddd, *J* 7.0, 9.5, 4.5 Hz), 2.91 (1H, dd, *J* 18.2, 7.0 Hz), 2.53 (1H, dd, *J* 18.2, 9.5 Hz), 2.40 (1H, m), 1.81 (3H, s), 0.84 (3H, d, *J* 6.8 Hz); (axial isomer) 6.48 (1H, s), 5.23 (1H, s), 4.15 (1H, m), 2.83 (1H, dd, *J* 18.3, 5.2 Hz), 2.60 (1H, dd, *J* 18.3, 2.5 Hz), 2.19 (1H, m), 1.81 (3H, s), 0.80 (3H, d, *J* 6.7 Hz), thus achieving two deprotections and a lactonisation in one step. It had been hoped that elimination would occur under these conditions to yield the α,β-unsaturated lactone. However, further treatment with mesyl chloride (MsCl) and Et_3N in refluxing dichloromethane for 12 h was necessary to achieve this transformation yielding (**13**) in 83% yield, $[\alpha]_D^{25}$ +81.4° (*c* 0.17, CH_2Cl_2). It was noted that the major axial isomer (**12b**) eliminated within minutes while the equatorial isomer (**12a**) required the refluxing conditions, thus confirming our original assignment.

The lactone was then reduced with di-isobutylaluminium hydride (DIBAL) to give one anomer; $[\alpha]_D^{22}$ +279.2° (*c* 0.27, CH_2Cl_2) and the lactol protected as a methyl acetal (Amberlite–H^+, MeOH, room temp., 12 h) to afford (**4**) as a colourless oil in 90% overall yield; $[\alpha]_D^{22}$ +485° (*c* 0.11, CH_2Cl_2), δ_H (360 MHz; $CDCl_3$) 6.28 (1H, s), 5.96 (1H, dd, *J* 9.6, 5.9 Hz), 5.61 (1H, dd, *J* 2.4, 9.6 Hz), 4.82 (1H, d, *J* 2.4 Hz), 4.36 (1H, s), 3.32 (3H, s), 2.15 (1H, m), 1.72 (3H, s), 0.71 (3H, d, *J* 7.1 Hz). This was then converted into the higher order cuprate[13] by treatment with two equivalents of Bu^tLi in diethyl ether at −80 °C under argon for 1.5 h to form the vinyl lithium which was then transferred *via* a cannula into a stirred suspension of CuCN (one equiv.) in diethyl ether at −40 °C and stirred for 1.5 h to form the higher order cuprate $[R_2Cu(CN)Li_2]$. The cuprate was then treated with the epoxide (**3**) (two equiv.) at −40 °C for 4 h then −20 °C for 24 h to yield the C-9—C-18 fragment (**14**) of macbecin in 35% yield§ as a colourless oil; $[\alpha]_D^{22}$ + 23.14° (*c* 0.15, CH_2Cl_2); δ_H (360 MHz; $CDCl_3$) 6.08 (1H, dd, *J* 9.6, 5.9 Hz), 5.70 (1H, dd, *J* 2.4, 9.6 Hz), 5.11 (1H, s), 4.92 (1H, br. s), 4.36 (1H, s), 3.77 (1H, m), 3.70 (1H, m), 3.48 (1H, m), 3.41 (3H, s), 2.27—2.13 (2H, m), 1.72 (3H, s), 1.29 (3H, d, *J* 5.2 Hz), 0.90 (9H, s), 0.83 (3H, d, *J* 7.0 Hz), 0.07 (6H, s).

We acknowledge an S.E.R.C. studentship (J. F. H.) and S.E.R.C. postdoctoral fellowships (W. J. C. and A. K.). We also thank Drs. C. J. Swain and M. J. O'Mahony for helpful discussions.

Received, 13th May 1986; Com. 641

References

1 S. Tanida, T. Hasegawa, and E. Higashide, *J. Antibiot.*, 1980, **33**, 199.
2 M. Muroi, M. Izawa, Y. Kasai, and M. Asai, *J. Antibiot.*, 1980, **33**, 205.
3 M. Muroi, K. Haibara, M. Asai, K. Kamiya, and T. Kishi, *Tetrahedron*, 1981, **37**, 1123.
4 C. DeBoer, P. A. Meulman, R. J. Wnuk, and D. H. Peterson, *J. Antibiot.*, 1970, **23**, 442.
5 S. Omura, Y. Iwai, Y. Takahashi, N. Sadakane, and A. Nakagawa, *J. Antibiot.*, 1979, **32**, 255.
6 S. Tanida, T. Hasegawa, K. Hatano, E. Higashide, and M. Yoneda, *J. Antibiot.*, 1980, **33**, 192.
7 R. K-Y. Zee-Cheng and C. C. Cheng, *Drugs of the Future*, 1984, **9**, 420.
8 D. A. Evans, P. L. Ornstein, and M. D. Ennis, 187th American Chemical Society National Meeting, April 8—13, St. Louis, 1984, MEDI-154.
9 K. B. Sharpless, B. E. Rossiter, and T. Katsuski, *J. Am. Chem. Soc.*, 1981, **103**, 463.
10 C. L. Rand, D. E. Van Horn, M. W. Moore, and E. Negishi, *J. Org. Chem.*, 1981, **46**, 4096.
11 D. A. Evans, J. Bartroli, and T. L. Shih, *J. Am. Chem. Soc.*, 1981, **103**, 2127.
12 A. J. Mancuso, S-L. Huang, and D. Swern, *J. Org. Chem.*, 1978, **43**, 2480.
13 For a general reference to organo cuprates see: B. H. Lipshutz, R. S. Wilhelm, and J. A. Kozlowski, *Tetrahedron*, 1984, **40**, 5005.

§ Based on the vinyl iodide.